Duncan Jacque L

Duncan Jacque L, Liang Wendi, Maguire Maureen G, Audo Isabelle, Ayala Allison R, Birch David G et al.

Birch David G, Duncan Jacque L, Samarakoon Lassana, Melia Michele, Audo Isabelle, Ayala Allison R et al.

This study found dark-adapted visual fields in USH2A patients worsen ~1 dB/year, comparable to full-field rod ERG changes. This highlights DAVF as a sensitive, clinically relevant measure of rod-mediated progression.

Parekh Bela, Peck-Dimit Nicholas, Duncan Jacque L, Samarakoon Lassana, Abalem Maria Fernanda, Andrews Chris A et al.

This study found the VALVVFQ-48 questionnaire may not be sensitive enough to track long-term functional vision changes in all USH2A patients, despite some decline in scores.

Duncan Jacque L, Maguire Maureen G, McDaniel Lee S, Doucet Nicole R, Audo Isabelle, Ayala Allison R et al.

This study tracked visual field loss in USH2A patients over 4 years, finding all measures declined, with peripheral vision and central sensitivity showing significant changes. These measures are useful for monitoring disease progression.

Duncan Jacque L, Liang Wendi, Maguire Maureen G, Audo Isabelle, Ayala Allison R, Birch David G et al.

Maguire Maureen G, Birch David G, Duncan Jacque L, Ayala Allison R, Ayton Lauren N, Cheetham Janet K et al.

This study identified sensitive measures for USH2A retinal degeneration trials, finding static perimetry's rate of change and microperimetry/FST's within-eye changes are key, informing future trial design.

MacLaren Robert E, Duncan Jacque L, Fischer M Dominik, Lam Byron L, Meunier Isabelle, Pennesi Mark E et al.

This 24-month study of XLRP patients found slow disease progression in functional and anatomical measures, providing crucial natural history data for future clinical trials.

Ku Cristy A, Igelman Austin D, Huang Samuel J, Bailey Steven T, Lauer Andreas K, Duncan Jacque L et al.

Voretigene neparvovec-rzyl caused perimacular atrophy in eyes previously treated with a different viral vector, despite visual gains. This highlights potential risks when using different gene therapy vectors in each eye.

Birch David G, Samarakoon Lassana, Melia Michele, Duncan Jacque L, Ayala Allison R, Audo Isabelle et al.

Dark-adapted visual fields revealed rod function in most USH2A patients, even without measurable rod ERGs, suggesting DAVF may be a sensitive tool for monitoring rod-mediated disease progression.

Duncan Jacque L, Liang Wendi, Maguire Maureen G, Audo Isabelle, Ayala Allison R, Birch David G et al.

This study found Usher syndrome type 2 patients had worse visual fields than USH2A-related ARRP. Visual field total hill of vision was a repeatable, reliable measure of disease severity, correlating with other functional and structural metrics.

Birch David G, Bennett Lea D, Duncan Jacque L, Weleber Richard G, Pennesi Mark E

CNTF implants for Retinitis Pigmentosa initially worsened visual field sensitivity, but this reversed upon removal. Long-term, these implants showed no benefit for vision or retinal structure.

Kuo Debbie S, Ou Yvonne, Jeng Bennie H, Bhisitkul Robert, Stewart Jay M, Duncan Jacque L et al.

Scleral pneumatonometry was studied as an alternative to corneal IOP measurement. It correlated well but read higher, suggesting it's a useful option when corneal measurements are unreliable or impossible.

Mkrtchyan Marianna, Lujan Brandon J, Merino David, Thirkill Charles E, Roorda Austin, Duncan Jacque L

This study found that focal outer retinal damage, particularly cone loss, directly correlates with vision loss in patients with AZOOR, highlighting high-resolution imaging's diagnostic value.

Thorne Jennifer E, Van Natta Mark L, Jabs Douglas A, Duncan Jacque L, Srivastava Sunil K

This study found visual field loss in CMV retinitis patients is 6x lower with HAART, and immune recovery significantly reduces this risk, highlighting the importance of immune status.

Cheung Marsha C, Nune George C, Hwang David G, Sutter Erich E, Duncan Jacque L

This case report found that acute zonal occult outer retinopathy (AZOOR) caused central vision loss in a patient with graft-versus-host disease (GVHD), suggesting GVHD should be considered an AZOOR-associated autoimmune condition.